These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 30121715)

  • 21. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
    Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
    Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
    J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The changing paradigm of management in melanoma brain metastases.
    Ladwa R; Atkinson V
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):453-458. PubMed ID: 29932306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory Reaction Secondary to Immune Checkpoint Inhibitor Therapy Mimicking a Post-Operative Brain Abscess.
    Patel AR; Connors S; Wardak Z; Brugarolas J; Patel TR
    World Neurosurg; 2019 Sep; 129():354-358. PubMed ID: 31203078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.
    Moraes FY; Taunk NK; Marta GN; Suh JH; Yamada Y
    Oncologist; 2016 Feb; 21(2):244-51. PubMed ID: 26764249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of systemic therapies in the management of melanoma brain metastases.
    Lyle M; Long GV
    Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
    Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of brain metastases according to molecular subtypes.
    Soffietti R; Ahluwalia M; Lin N; Rudà R
    Nat Rev Neurol; 2020 Oct; 16(10):557-574. PubMed ID: 32873927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of systemic precision medicine and immunotherapy treatments on brain metastases.
    Han RH; Dunn GP; Chheda MG; Kim AH
    Oncotarget; 2019 Nov; 10(62):6739-6753. PubMed ID: 31803366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic agents in the management of brain metastases.
    Venur VA; Ahluwalia MS
    Curr Opin Oncol; 2017 Sep; 29(5):395-399. PubMed ID: 28787285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma brain metastases: an unmet challenge in the era of active therapy.
    Gorantla V; Kirkwood JM; Tawbi HA
    Curr Oncol Rep; 2013 Oct; 15(5):483-91. PubMed ID: 23954973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.
    Jindal V; Gupta S
    Mol Neurobiol; 2018 Aug; 55(8):7072-7078. PubMed ID: 29383686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment.
    Trommer-Nestler M; Marnitz S; Kocher M; Rueß D; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Jablonska K; Celik E; Ruge MI; Baues C
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.
    Venur VA; Funchain P; Kotecha R; Chao ST; Ahluwalia MS
    Oncology (Williston Park); 2017 Sep; 31(9):659-67. PubMed ID: 29071693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
    Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
    Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.